Biopharmaceutical company Sophiris Bio ( SPHS ) said pre-market Thursday it began dosing patients in its phase 2b study to evaluate the safety and tolerability of topsalysin in focally treating men with clinically significant localized prostate cancer.
Topsalysin (PRX302) is a protein engineered to be activated only in the presence of enzymatically-active PSA, which is only found within the prostate.
"Topsalysin has the potential to provide a much-needed opportunity to treat the patients who have clinically significant localized prostate cancer," said Hashim Ahmed, professor and chair of urology, Imperial College London. "This would be extremely exciting and clinically meaningful for men, as it could help them either avoid or delay the need for radical therapies and significant side effects associated with radical therapy."
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
